Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 194Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 179Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 153Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 120Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Advanced Solid Tumors 106Brain Neoplasms 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

MRX-2843 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplastic Processes × 1 year × Clear all
NCT03510104 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

Meryx, Inc.

Phase 1 Completed
42 enrolled

Neoplasm Metastasis, Neoplasms, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡